Gopinath B et al., “Consumption of omega-3 fatty acids and fish and risk of age-related hearing loss,” American Journal of Clinical Nutrition, vol. 92, no. 2 (August 2010): 416-421.
Omega-3 intake may reduce the likelihood of developing age-related hearing loss, according to results from a large-scale Australian population study.
Researchers analyzed data on 2956 subjects (age 50 or older) who submitted food frequency questionnaires in the Blue Mountains Eye Study and Hearing Study from 1997-1999 to 2002-2004. The study aimed to identify any link between omega-3 intake and incidence of presbycusis (age-related hearing loss). Omega-3 intake was classified as the amount of fish eaten per week by subjects.
Data indicated that subjects who ate two or more servings of fish per week experienced a 42% reduced risk of presbycusis compared to those who ate fish less than once per week. “Dietary intervention with [omega-3s] could prevent or delay the development of age-related hearing loss,” wrote the study’s authors.
The Blue Mountains Eye Study and Hearing Study were funded by grants from the Australian National Health and Medical Research Council.
GC Rieber VivoMega uses AI platform from Intelecy to boost efficiency, quality, and sustainability
August 26th 2024According to the company’s announcement, the AI platform is able to identify real-time deviations or anomalies in GC Rieber VivoMega’s processing facilities and report them via a cloud-based, comprehensive, centralized system.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
GC Rieber VivoMega uses AI platform from Intelecy to boost efficiency, quality, and sustainability
August 26th 2024According to the company’s announcement, the AI platform is able to identify real-time deviations or anomalies in GC Rieber VivoMega’s processing facilities and report them via a cloud-based, comprehensive, centralized system.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
2 Commerce Drive
Cranbury, NJ 08512